Bone metastasis
Conditions
Interventions
zoledronic acid group:zoledronic acid
denosumab group:denosumab
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients with bone metastasis confirmed by histology or cytology were examined by X-ray, CT or MRI, which indicated that there was at least one bone metastasis or characteristic osteolytic lesion; 2. Patients who have bone related events and receive radiotherapy, surgery, chemotherapy, targeted therapy or multiple combination therapy; 3. The score of physical fitness in the Eastern Cooperative Oncology Group (ECoG) was 0-2 for patients with malignant tumors involving organs other than organs with good function; 4. Patients over 18 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with primary bone tumor or hematological tumor; 2. Patients who had used zoledronic acid or dinosemide before this treatment; 3. Patients with expected survival less than 6 months; 4. Patients with mandibular necrosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;PFS;adverse reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frankel score;Vas score;QOL; | — |
Countries
China
Contacts
Public ContactJianru Xiao
Department of Orthopaedic Oncology, Shanghai Changzheng Hospital
Outcome results
None listed